Levels of Peripheral Th17 Cells and Th17-Related Cytokines in Patients with Ankylosing Spondylitis: A Meta-analysis.
Ankylosing spondylitis
IL-17
IL-21
IL-23
Th17
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
07
05
2022
accepted:
22
06
2022
pubmed:
13
8
2022
medline:
14
9
2022
entrez:
12
8
2022
Statut:
ppublish
Résumé
Ankylosing spondylitis (AS) is a chronic inflammatory disease. Several proinflammatory cytokines produced by T helper 17 (Th17) cells are involved in the pathogenesis of AS. We performed a meta-analysis to determine the levels of Th17 cells and serum Th17-associated cytokines in patients with AS. We determined the levels of Th17 cells and Th17 cytokines in patients with AS using data extracted from published articles retrieved from the PubMed, Embase, Web of Science, Cochrane Library, MEDLINE, Web of Knowledge, Clinical Trials.gov, and FDA.gov. The effect estimates were pooled using a random-effects model. The review protocols were registered on PROSPERO (reference: CRD42021255741) and followed the PRISMA guideline. This meta-analysis included 138 studies. Compared to healthy controls (HCs), patients with AS had a higher proportion of Th17 cells (standardized mean difference [SMD] 2.23, 95% confidence interval [CI] 1.78-2.68; p < 0.001) and levels of proinflammatory cytokines, such as interleukin (IL)-17 (SMD 2.04, 95% CI 1.70-2.38; p < 0.001), IL-21 (SMD 1.77, 95% CI 0.95-2.59; p < 0.001), and IL-23 (SMD 1.11, 95% CI 0.78-1.44; p < 0.001). The subgroup analysis showed higher levels of IL-17 The levels of Th17 cells and serum IL-17, IL-21, and IL-23 were higher in patients with AS than in HCs and, compared with stable AS, they increased more significantly in active AS. These results suggest that Th17 cells and Th17-related cytokines play major roles in AS pathogenesis and are an important target for treatment.
Sections du résumé
BACKGROUND
Ankylosing spondylitis (AS) is a chronic inflammatory disease. Several proinflammatory cytokines produced by T helper 17 (Th17) cells are involved in the pathogenesis of AS. We performed a meta-analysis to determine the levels of Th17 cells and serum Th17-associated cytokines in patients with AS.
METHODS
We determined the levels of Th17 cells and Th17 cytokines in patients with AS using data extracted from published articles retrieved from the PubMed, Embase, Web of Science, Cochrane Library, MEDLINE, Web of Knowledge, Clinical Trials.gov, and FDA.gov.
DATABASES
The effect estimates were pooled using a random-effects model. The review protocols were registered on PROSPERO (reference: CRD42021255741) and followed the PRISMA guideline.
RESULTS
This meta-analysis included 138 studies. Compared to healthy controls (HCs), patients with AS had a higher proportion of Th17 cells (standardized mean difference [SMD] 2.23, 95% confidence interval [CI] 1.78-2.68; p < 0.001) and levels of proinflammatory cytokines, such as interleukin (IL)-17 (SMD 2.04, 95% CI 1.70-2.38; p < 0.001), IL-21 (SMD 1.77, 95% CI 0.95-2.59; p < 0.001), and IL-23 (SMD 1.11, 95% CI 0.78-1.44; p < 0.001). The subgroup analysis showed higher levels of IL-17
CONCLUSIONS
The levels of Th17 cells and serum IL-17, IL-21, and IL-23 were higher in patients with AS than in HCs and, compared with stable AS, they increased more significantly in active AS. These results suggest that Th17 cells and Th17-related cytokines play major roles in AS pathogenesis and are an important target for treatment.
Identifiants
pubmed: 35960483
doi: 10.1007/s12325-022-02240-z
pii: 10.1007/s12325-022-02240-z
doi:
Substances chimiques
Cytokines
0
Interleukin-17
0
Interleukin-23
0
Types de publication
Journal Article
Meta-Analysis
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4423-4439Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.
doi: 10.1016/S0140-6736(16)31591-4
Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927–31.
doi: 10.1093/rheumatology/33.10.927
Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304–5.
doi: 10.1016/j.jbspin.2006.11.005
Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647–56.
doi: 10.1002/art.24568
Liu D, Liu B, Lin C, Gu J. Imbalance of peripheral lymphocyte subsets in patients with ankylosing spondylitis: a meta-analysis. Front Immunol. 2021;12: 696973.
doi: 10.3389/fimmu.2021.696973
Qian Y, Kang Z, Liu C, Li X. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol. 2010;7(5):328–33.
doi: 10.1038/cmi.2010.27
Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.
doi: 10.1038/ni1261
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–76.
doi: 10.1038/nrd3794
Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Adv Immunol. 2011;109:159–96.
doi: 10.1016/B978-0-12-387664-5.00005-4
Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol. 2008;20(4):392–7.
doi: 10.1097/BOR.0b013e328303204b
Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283–97.
doi: 10.1007/s00281-019-00733-8
Xie J, Wang Z, Wang W. Semaphorin 4D induces an imbalance of Th17/Treg cells by activating the aryl hydrocarbon receptor in ankylosing spondylitis. Front Immunol. 2020;11:2151.
doi: 10.3389/fimmu.2020.02151
Bautista-Caro MB, Arroyo-Villa I, Castillo-Gallego C, et al. Decreased Th17 and Th1 cells in the peripheral blood of patients with early non-radiographic axial spondyloarthritis: a marker of disease activity in HLA-B27(+) patients. Rheumatology (Oxford). 2013;52(2):352–62.
doi: 10.1093/rheumatology/kes267
Ulrich J, Probst A, Anderton BH, Kahn J. Dementia of Alzheimer type (DAT)—a review of its morbid anatomy. Klin Wochenschr. 1986;64(3):103–14.
doi: 10.1007/BF01732633
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.
doi: 10.1136/bmj.b2535
Mingebach T, Kamp-Becker I, Christiansen H, Weber L. Meta-meta-analysis on the effectiveness of parent-based interventions for the treatment of child externalizing behavior problems. PLoS One. 2018;13(9): e0202855.
doi: 10.1371/journal.pone.0202855
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .
Matsuda A. Diabetic gangrene—physiopathology and management. Kango Gijutsu. 1979;25(16):105–15.
pubmed: 260746
Akimzhanov AM, Yang XO, Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem. 2007;282(9):5969–72.
doi: 10.1074/jbc.C600322200
Wilson AS, Randall KL, Pettitt JA, et al. Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2. Nat Commun. 2022;13(1):528.
doi: 10.1038/s41467-022-28172-4
Marks KE, Rao DA. T peripheral helper cells in autoimmune diseases. Immunol Rev. 2022;307:191–202.
doi: 10.1111/imr.13069
Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014;35(10):493–500.
doi: 10.1016/j.tips.2014.07.006
Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019;15(12):747–57.
doi: 10.1038/s41584-019-0294-7
Cao W, Wang X, Chen T, et al. The expression of notch/notch ligand, IL-35, IL-17, and Th17/Treg in preeclampsia. Dis Markers. 2015;2015: 316182.
doi: 10.1155/2015/316182
McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906.
doi: 10.1016/j.immuni.2019.03.021
Lubberts E. The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415–29.
doi: 10.1038/nrrheum.2015.53
Jethwa H, Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol. 2016;183(1):30–6.
doi: 10.1111/cei.12670
Burkett PR, Meyer zu Horste G, Kuchroo VK. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Investig. 2015;125(6):2211–9.
doi: 10.1172/JCI78085
Gravallese EM, Schett G. Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14(11):631–40.
doi: 10.1038/s41584-018-0091-8
Bridgewood C, Sharif K, Sherlock J, Watad A, McGonagle D. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev. 2020;294(1):27–47.
doi: 10.1111/imr.12840
McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9.
doi: 10.1016/S0140-6736(13)60594-2
Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302.
doi: 10.1136/annrheumdis-2018-213328
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.
doi: 10.1038/nri3707
McGonagle D, Watad A, Sharif K, Bridgewood C. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021;12: 614255.
doi: 10.3389/fimmu.2021.614255
Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2019;78(8):1015–8.
doi: 10.1136/annrheumdis-2018-213654
Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature. 2012;484(7395):514–8.
doi: 10.1038/nature10957
Yang PT, Kasai H, Zhao LJ, Xiao WG, Tanabe F, Ito M. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138(2):342–7.
doi: 10.1111/j.1365-2249.2004.02617.x
Maeda S, Osaga S, Maeda T, et al. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: an exploratory research. PLoS One. 2019;14(11): e0215192.
doi: 10.1371/journal.pone.0215192
Mease P, van den Bosch F. IL-23 and axial disease: do they come together? Rheumatology (Oxford). 2021;60(Suppl 4):iv28–33.
doi: 10.1093/rheumatology/keab617